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Transfusion burden in non-dialysis chronic kidney
disease patients with persistent anemia treated in
routine clinical practice: a retrospective
observational study
Kathleen M Fox1*, Jerry Yee2, Ze Cong3, John M Brooks4, Jeffrey Petersen5, Lois Lamerato6 and
Shravanthi R Gandra3

Abstract
Background: Transfusion patterns are not well characterized in non-dialysis (ND) chronic kidney disease (CKD)
patients. This study describes the proportion of patients transfused, units of blood transfused and triggerhemoglobin (Hb) levels for transfusions in severe anemic, ND-CKD patients in routine practice.
Methods: A retrospective cohort study of electronic medical record data from the Henry Ford Health System
identified 374 adult, ND-CKD patients with severe anemia (Hb < 10 g/dL and subsequent use of erythropoiesisstimulating agents [ESA] therapy, blood transfusions, or a second Hb < 10 g/dL) between January 2004 and June
2008. Exclusions included those with prior diagnoses of cancer, renal or liver transplant, end-stage renal disease,
acute bleeding, trauma, sickle cell disease, or aplastic anemia. A gap of ≥ 1 days between units of blood transfused
was counted as a separate transfusion.
Results: At least 1 transfusion (mean of 2 units; range, 1-4) was administered to 20% (75/374) of ND-CKD patients
with mean (± SD) follow-up of 459 (± 427) days. The mean (± SD) Hb level closest and prior to a transfusion was
8.8 (± 1.5) g/dL. Patients who were hospitalized in the 6 months prior to their first anemia diagnosis were 6.3 times
more likely to receive a blood transfusion than patients who were not hospitalized (p < 0.0001). Patients with
peripheral vascular disease (PVD) were twice as likely to have a transfusion as patients without PVD (p = 0.04).
Conclusions: Transfusions were prevalent and the trigger hemoglobin concentration was approximately 9 g/dL
among ND-CKD patients with anemia. To reduce the transfusion burden, clinicians should consider other anemia
treatments including ESA therapy.

Background
Chronic kidney disease (CKD) affects about 26 million
adults (11%) in the United States, with the early stages
(stages 3-4) being approximately 100 times more prevalent than kidney failure [1]. Persistent anemia is a consequence of the declining endogenous erythropoietin
production seen in progressive CKD [2]. Anemia of
CKD can be successfully treated by administration of an
erythropoiesis-stimulating agent (ESA) [3]. Blood transfusion in non-dialysis (ND) CKD occurs in nearly 10%
* Correspondence: kathyfox@gforcecable.com
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of Medicare-insured CKD patients per year despite the
availability of ESA therapy, a rate four times as great as
in older patients without CKD [4]. The use of transfusion can correct anemia in the short term, but may also
increase the risk of sensitization to HLA antibodies and
thus delay or even preclude kidney transplant [5]. Additional risks associated with transfusion include iron
overload, transfusion reactions, transmission of infectious agents, and acute lung injury [5].
Studies in CKD patients on dialysis have shown a
declining pattern of transfusion use subsequent to the
introduction and adoption of anemia management with
ESAs [6]. However, in the ND-CKD setting, the pattern
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of use of transfusion among patients with CKD-related
anemia has not been well characterized. The present
study describes the proportion of patients transfused
among severe anemic ND-CKD patients who were managed in routine clinical practice. The study objectives
were to estimate the proportion of ND-CKD patients
receiving transfusions, to estimate the exposure-adjusted
transfusion rate, and to characterize the patients who
received a transfusion, among severely anemic, NDCKD patients.

Methods
A retrospective observational cohort study was conducted using electronic medical record data collected by
the Henry Ford Health System (HFHS). The Henry Ford
Health System is a vertically integrated health care system providing clinical services to a diverse Michigan
community, with over 2.5 million patient visits and
65,000 hospital admissions annually. HFHS is the largest
integrated health system in southeast Michigan area and
the patient population is relatively stable. Administrative
data was linked to clinical, pharmacy, and laboratory data
for eligible patients.
Study population

All HFHS patients, 18 years of age or older, who had a
diagnosis of CKD stage 3-5, and were not on dialysis during the study intake period of January 1, 2004 and June
30, 2008 were identified. A diagnosis of CKD stage 3-5
was defined as the presence of at least 2 ICD-9 codes for
CKD (585.xx, 403.xx, 404.xx) within 6 months and an
eGFR ≥ 15 and < 60 mL/min/1.73 m 2 estimated using
the CKD-EPI equation [1]. Two or more ICD-9 codes for
CKD were required to rule out patients who might have
received 1 ICD-9 code during the initial work-up of the
diagnosis.
To be included in the study, these CKD patients had to
have severe anemia that was defined, for the purpose of
this study, as hemoglobin (Hb) < 10 g/dL and at least one
of the following subsequent events (within 6 months):
1) received ESA therapy, 2) had a blood transfusion, or
3) second Hb < 10 g/dL. The criterion of at least one
additional event (ESA therapy, transfusion, or second
Hb < 10 g/dL) was used to include patients with nonacute, severe anemia that was related to CKD. The index
date was the date of the first Hb < 10 g/dL, i.e., first
observed date with an indication of severe anemia. Patients
with the following conditions 6 months prior to the index
date or any time during follow-up were excluded from the
analysis in an attempt to eliminate reasons for transfusion
other than CKD-related anemia: cancer, acute bleeding
episodes, gastrointestinal surgery, sickle cell or aplastic
anemia, recent trauma and liver transplant. Patients who
had end stage renal disease (ESRD), or received kidney
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transplant, hemodialysis or peritoneal dialysis prior to the
index date were also excluded. The follow-up period
began with the index date (date of first Hb < 10 g/dL) and
not the subsequent event of ESA therapy, transfusion, or
second Hb < 10 g/dL since this event may occur at any
time during the 6 months after the index date. Eligible
patients were followed until one of the following events
transpired in the follow-up period: 1) initiation of dialysis
or development of ESRD (diagnostic code), 2) renal transplantation, 3) death, or 4) last date of data capture, i.e.
December 31, 2009.
Study variables

The study outcome was any blood transfusion (inpatient
or outpatient) occurring during the follow-up period. A
transfusion was defined as all units of blood transfused on
consecutive days; a gap of 1 or more days between transfused units of blood was counted as a separate transfusion.
This definition was applied to account for patients who
had a transfusion order late in the day such that the last
unit of blood was transfused on the following day. Exposure-adjusted transfusion rate was calculated as the total
number of transfusions divided by total person time during follow-up and reported per 100 patient-years. This
rate was calculated to adjust for the varying length of follow-up among patients since some patients may have
died, progressed to ESRD, started dialysis or dropped out.
The number of units given during each transfusion was
summarized. Baseline hemoglobin was the hemoglobin
concentration 30 days preceding the index date. The
post-index Hb concentration closest to but prior to
(within 2 days) the transfusion was considered the trigger
Hb for the transfusion. Comorbid conditions (i.e. cardiovascular disease, peripheral vascular disease, diabetes,
hypertension, dyslipidemia, cerebrovascular disease) were
captured in the 6 months prior to the index date. ICD-9
diagnosis codes in the primary or secondary position on
any non-diagnostic claim were used to identify comorbid
conditions. Occurrence of transfusion, care visit to a
nephrologist, and hospitalization in the 6 months prior to
the index date were recorded.
The study was approved by the Henry Ford Health
System Institutional Review Board.
Statistical analysis

Means and variances were calculated for continuous variables and number and percent of patients for categorical
variables. Univariate analysis compared the proportion of
patients transfused for each patient characteristic (chisquare, t tests, and Mann-Whitney U test for median
length of follow-up) and those characteristics that had a
P < 0.10 were entered into a multivariable analysis. Multivariable logistic regression analysis was conducted to
estimate the likelihood of a blood transfusion, adjusting
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for patient demographics and clinical characteristics. All
variables were entered into the model simultaneously
without a stepwise procedure. Variables included in the
model were those that were demographic variables (age,
gender, and race) and clinical characteristics assessing
patient’s health status at baseline (comorbid conditions
and prior nephrologist visit) regardless of the significance
level in the univariate analysis. Characteristics that were
significantly associated with transfusion in univariate
analysis (P < 0.10) were also included in the same model.
Unique ICD-9 codes were used for the comorbid conditions of cardiovascular disease and peripheral vascular
disease. Continuous covariates were stratified at the
mean, below the mean vs. at or above the mean. Odds
ratios and 95% confidence intervals were calculated.

Results
There were 3,075 CKD patients stage 3-5 in the HFHS
between January 1, 2004 and June 30, 2008. One-third
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of patients (32%) did not meet our definition for severe
anemia, or had claims indicating the presence of ESRD
or dialysis at the index date, a history of cancer, or
other blood-related conditions that influence the likelihood of anemia (Figure 1). A cohort of 374 patients
had non-dialysis, CKD with severe anemia and was
included in the analysis. Among the 374 patients, 303
(81%) were included in the cohort because they had a
second Hb < 10 g/dL which occurred, on average,
within 15 days of the first Hb < 10 g/dL; 83 patients
had an ESA prescribed within an average of 21 days
after the first Hb < 10 g/dL, and 13 patients had a
blood transfusion within an average of 5 days after the
first Hb < 10 g/dL.
The cohort comprised mostly older patients (mean age
of 71 years) and women (60%) with approximately 66%
of the cohort having seen a nephrologist prior to the
index date (Table 1). There were 75 patients who had at
least 1 transfusion in the follow-up period.

3,075 CKD Stage 3-5 in
Henry Ford Health System
between Jan. 1, 2004 and June 30, 2008

1,359 patients with
chronic anemia

Patient exclusions:

162 with <12 months of data prior to anemia index date
379 cancer
242 with ESRD or dialysis
166 with liver transplant, acute bleeding, sickle cell or aplastic anemia, or
trauma from 6 months prior to and until end of follow-up
36 Received dialysis /ESRD or transplant within 6 months prior

374 Eligible
patients

303 patients with 2nd Hb < 10 g/dL
83 patients with ESA after 1st Hb < 10 g/dL
13 patients with transfusion after 1st Hb <10 g/dL
Figure 1 Non-dialysis CKD patients with persistent anemia: inclusion and exclusion chart.
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Table 1 Characteristics of the Henry Ford cohort of nondialysis CKD patients with persistent anemia
Characteristics

Total cohort N =
374

Age, mean (SD)

70.8 (12.9)

Men, %

39.6

White, %

45.7

African American, %
eGFR at index date†, mean (SD)

50.3
32.1 (12.7)

Hemoglobin closest to index date (baseline),
%
< 10 g/dL

8.5

≥ 10 g/dL

91.5

Transfusion prior to index date, %

3.5

Cardiovascular disease, %

36.6

Diabetes, %

59.1

Peripheral vascular disease

16.6

Nephrologist visit prior to index date, %

66.3

Hospitalized prior to index date, %

49.7

Follow-up period, days, mean (SD)

459.5 (427.4)

†index date is the date of the first Hb < 10 g/dL in the study identification
period.

Proportion transfused and transfusion rates

The proportion of patients who had a transfusion was 20%
for the cohort; 14% of the cohort had only 1 transfusion,
3% had 2 transfusions and 3% had 3 or more transfusions.
The proportion transfused was greater among patients
with peripheral vascular disease (PVD) at baseline than
among patients without PVD (29% vs. 18%, respectively,
P = 0.05) (Table 2). In addition, more African American
and other minority patients had a transfusion (25% and
27%, respectively) than white patients (14%) (P = 0.05).
A larger percentage of patients with a hospitalization
during the 6-month pre-period had a transfusion compared to those without a prior hospitalization (33% vs.
7%, respectively, P < 0.0001, Table 2). Additionally, the
frequency of patients who had a transfusion was larger
among those with more hospital days before the anemia
index date (more than 5 days over a 6-month period;
mean number of hospital days was 5) compared to those
with fewer hospital days (34% vs. 13%, respectively, P <
0.0001). Among patients who had a transfusion prior to
their anemia index date, the proportion transfused during
follow-up was larger than among patients who did not
previously have a transfusion (38% vs. 19%, respectively,
P = 0.09); however, only 13 patients had a prior transfusion. The percentage of patients who had a transfusion
did not differ by CKD stage, gender, age, baseline eGFR,
Hb prior and closest to index date, comorbid conditions
of diabetes, hypertension, cardiovascular disease, dyslipidemia, and cerebrovascular disease, or nephrology visit
prior to anemia index date.

The patient cohort had an average (± SD) length of follow-up of 459 (427) days. The average exposure-adjusted
transfusion rate was 182.2 transfusions per 100 patientyears. The rate of transfusions was higher among patients
who had a hospitalization prior to the index date (343.5
vs. 22.6 per 100 patient-years, P = 0.0004). Patients with
more than 5 days in the hospital during the 6-month
interval prior to the index date had a higher rate of transfusion than patients with 4 or fewer hospital days (478.7
vs. 38.7 per 100 patient years) (P = 0.001). With exposure
adjustment, the rate of transfusion was not statistically different between groups with PVD (266 vs. 165, P = 0.40),
or a history of transfusion (830 vs. 159, P = 0.17). However, patients with cardiovascular disease (CVD) at baseline had a significantly higher rate of transfusions (322.4
per 100 patient years) compared with patients without
CVD (101.2 per 100 patient-years) (P = 0.04).
Multivariable logistic regression analysis estimated the
likelihood of a blood transfusion adjusting for age, gender,
race, history of blood transfusion, prior nephrologist visit,
prior hospitalization, and comorbid conditions (Table 3).
Length of follow-up was similar between transfused
patients (median of 434 days, IQR of 80-735) and patients
with no transfusion (466 days, IQR of 87.5-698.5, P =
0.57). Patients who were hospitalized prior to their anemia
index date were 5.6 times more likely to receive a blood
transfusion than patients who were not hospitalized (P <
0.0001). Age, gender, race, prior transfusion, prior
nephrologist visit, diabetes, cardiovascular disease, and
peripheral vascular disease were not independently significantly associated with the likelihood of transfusion after
adjusting for other covariates. Cox proportional hazards
regression was also conducted with the results being very
similar (similar hazards as odds ratios) to the logistic
regression.
Transfusion characteristics

Approximately, 94% of transfusions occurred in the hospital inpatient setting, while 6% were administered in
the ambulatory care setting. Among those patients who
were transfused, the mean number of transfusions was
1.6 (SD = 1.0) and an average of 2 units of blood were
transfused per transfusion. For 19.5% of the 123 transfusions, 1 unit of blood was transfused, 66% of transfusions had 2 units of blood transfused and 6.5% of
transfusions had 3 units of blood transfused (Figure 2).
A total of 24 patients had multiple transfusions, 18 of
whom had ≥ 5 days between transfusions and 6 of
whom had ≤ 4 days between transfusions.
Trigger hemoglobin

The hemoglobin value closest and prior to (within 2
days) each transfusion was examined and the mean Hb
level was 8.8 (SD = 1.5) g/dL. Approximately 12.5% of
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Table 2 Proportion of patients with a transfusion by patient characteristics
Characteristic

Proportion of patients transfused, %

Age

p-value
0.95

18-64 years, n = 105

19

65-74 years, n = 99

20

75 or older, n = 170

21

Gender

0.86

Male, n = 148

20

Female, n = 226

20

Race

0.054

Caucasian, n = 171

14

African American, n = 188

25

Other races, n = 15

27

Transfusion in the pre-index period

0.09

Yes, n = 13

38

No, n = 361

19

eGFR, mL/min/1.73 m2, in the pre-index period

0.82

< 15, n = 13

15

15 to < 30, n = 135

21

30 to < 45, n = 101

19

45 to ≤ 60, n = 36

22

Nephrologist visit in pre-index period

0.31

Yes, n = 248

19

No, n = 126

23

Hospitalization in pre-index period

< 0.0001

Yes, n = 186

33

No, n = 188

7

Comorbid condition in pre-index period
Diabetes

0.38

Yes, n = 221

19

No, n = 153

22

Peripheral vascular disease

0.053

Yes, n = 62

29

No, n = 312

18

Cardiovascular disease

0.14

Yes, n = 137

24

No, n = 237

18

transfusions were preceded by a Hb between 9.0 and 9.9
g/dL, 36.5% were preceded by a Hb between 8.0 and 8.9
g/dL, and 20% were preceded by a Hb between 7.0 and
7.9 g/dL (Figure 3). There were two transfusions where
the closest Hb assessment was > 3 days from the transfusion and these values were not included in the analysis
of trigger hemoglobin.

Discussion
Blood transfusions were prevalent among ND-CKD
patients with severe anemia recently treated within the

Henry Ford Health System. Prior hospitalization consistently predicted a higher transfusion rate among these
patients and patients with more days in the hospital
prior to the anemia index date had more transfusions. A
hemoglobin concentration around 9 g/dL was the mean
level closest to the transfusion, indicative that this level
may be the trigger for a blood transfusion in this population although a substantial proportion occurred at Hb
> 9.0 g/dL. These findings provide new evidence of the
transfusion burden among anemic ND- CKD patients
treated in routine clinical practice.
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Table 3 Likelihood of blood transfusion among non-dialysis CKD patients with persistent anemia using multivariate
logistic regression
Bivariate analysis
Characteristics
Male (ref: female)

Multivariate logistic regression

Proportion with
transfusion

P-value

Odds
ratio

95% Confidence
Interval

P-value

20% males, 20% females

0.86

0.89

0.51-1.56

0.69

14%

0.054

Race (ref: Caucasian)
African American

25%

1.45

0.80-2.61

0.22

Other minority race

27%

1.80

0.48-6.68

0.38

Age (ref: < 65 years)

19%

Age 65-74 years

20%

0.95
0.98

0.47-2.07

0.96

Age ≥ 75 years

21%

1.20

0.60-2.37

0.61

Prior transfusion (ref: no prior transfusion)

38% yes, 19% no

0.09

1.05

0.39-2.84

0.92

Prior nephrologist visit (ref: no prior nephrologist
visit)

19% yes, 23% no

0.31

0.99

0.56-1.75

0.98

Prior hospitalization (ref: no prior hospitalization)

33% yes, 7% no

<
0.0001

5.64

2.90-10.96

<
0.0001

19% yes, 22% no

0.38

0.83

0.47-1.45

0.51

Peripheral vascular disease

29% yes, 18% no

0.053

1.79

0.90-3.54

0.09

Cardiovascular disease

24% yes, 18% no

0.14

1.02

0.56-1.83

0.96

Comorbid conditions within 6 months prior to index
date
Diabetes

Veterans Health Administration (VHA) between 2003 and
2005. The VHA study required patients to have only 1 Hb
< 11 g/dL to be included in the study. In comparison, the
proportion of patients who had a transfusion of 20% in the
present study may be higher due to differences in the
composition of the study population; in the VHA study,

A few other studies have provided estimates of transfusion frequency for anemic non-dialysis CKD patients;
however, these studies included unique patient populations and less current practice trends. Lawler and colleagues [7] observed a transfusion frequency of 8.5%-15.6%
among patients with Hb < 11 g/dL receiving care in the

1

2

3

4

5

6

7

Figure 2 Number of units of blood transfused per transfusion among non-dialysis CKD patients with persistent anemia.

8
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Figure 3 Hemoglobin level closest and prior to the transfusion among non-dialysis CKD patients with persistent anemia.

80% of patients were white, 97% of patients were men, and
the definition of anemia differed compared to our study.
The present study also evaluated transfusion burden
among severe anemia defined as Hb < 10 g/dL and confirmation with subsequent treatment or second Hb < 10 g/
dL) non-dialysis CKD patients. A study of Medicare beneficiaries [4] between 1992 and 2004 observed an adjusted
transfusion rate of 112.2 per 1000 patient-years in 2004,
which is lower than the present study adjusted rate of 182.2
per 100 patient-years. The higher transfusion frequency in
the present study may be due to the following factors:1)
inclusion of only stage 3-5 CKD with confirmed anemia
whereas the Ibrahim study [4] included all CKD stages with
approximately 60% of patients without anemia, 2) inclusion
of patients enrolled in a commercial health plan (HFHS
managed care) whereas Ibrahim excluded commercial
health plan members and focused on Medicare patients, 3)
significantly larger proportion of African Americans (50%)
compared with 15% in the Ibrahim study, and 4) current
trends in utilization of transfusion (up to December 2009)
with longer follow-up time than the 1 year point prevalence
of the Ibrahim study. The HFHS did not follow a defined
transfusion protocol during the time of this study but the
clinical directive was to maintain Hb at 10 g/dL or higher.
With the goal of maintaining Hb ≥ 10 g/dL, patients’ anemia symptoms (e.g. fatigue, lack of energy) and consequences of potential allosensitization were considered in
the clinical decision to transfuse CKD patients.
Based on treatment patterns observed among CKD
patients treated at the HFHS, a hemoglobin level around

9 g/dL appears to trigger the majority of blood transfusions. However, approximately 21% of transfusions
occurred when the closest, preceding Hb level was ≥ 10 g/
dL. This may be because more than one-third (38%) of the
high Hb (≥ 10 g/dL) transfusions were second and subsequent transfusions and the treating physician may not
have waited for the Hb results to order subsequent transfusions given the patient’s medical history. Additionally,
the reasons for transfusions might not be solely based on
the Hb levels; patients’ symptoms will also influence physician’s decisions.
A key reason for patients with CKD to avoid blood
transfusions is the risk of developing allo-antibodies which
prolong the time on the kidney transplant waiting list and
possibly jeopardize the kidney transplant outcome [8]. In
addition, blood transfusions are not without risks, including transfusion reactions, transmission of infectious
agents, and iron overload [9]. Providing adequate iron
stores and using ESAs, may help to reduce the need for
transfusions. A better understanding of the reasons for
blood transfusions may help to elucidate other pathways
to reducing the transfusion burden.
Minority races (African American and other races)
had a higher unadjusted rate of transfusion than Whites
but after controlling for other characteristics, the
adjusted transfusion rate did not differ across racial
groups. This may be due to the small number of
patients who received transfusions in this study; 24
Whites, 47 African Americans and 4 other races were
transfused in this study.
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Several study limitations should be considered. The
population served by HFHS is primarily from the greater
metropolitan Detroit, MI area. As such this region may
not be representative of the US population and have different treatment patterns for CKD-related anemia. Thus,
the study findings may be limited to non-dialysis CKD
patients with anemia and not generalizable to all CKD
patients. The definition for severe anemia used in the
study is limited in capturing chronic, severe anemia since
it used one Hb < 10 g/dL followed by treatment or a second Hb < 10 g/dL. Of the 303 patients included in the
cohort with a second Hb < 10 g/dL, 60% had the second
Hb level 1-2 days after the first Hb so the anemia may not
be chronic or persistent for some patients. Also, only 75
patients received transfusion during the study period,
which limited the likelihood to observe statistically significant differences. For example, 13 patients had a prior
transfusion and only 5 of these 13 patients had a transfusion during follow-up.

Conclusions
Blood transfusions were prevalent among ND- CKD
patients with persistent anemia; 20% of patients were
transfused. The mean hemoglobin level closest and prior
to transfusion was around 9 g/dL and an average of 2
units of blood was transfused per transfusion. Prior hospitalization is strongly predictive of a higher transfusion
rate.
Abbreviations
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